权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

BIOLOGICAL TESTING FACILITY - CONTRACEPTIVE TARGET WEB APPLICATION

生物测试设施 - 避孕目标网络应用程序

基本信息

批准号：
10176115
负责人：
TOUFAN PARMAN
金额：
$ 11万
依托单位：
SRI INTERNATIONAL
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-27 至 2020-09-26
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10176115
关键词：
Acetates Adrenal Cortex Hormones Adrenal Glands Androgen Antagonists Androgens Animal Welfare Act Animals Anti-Inflammatory Agents Antibodies Area Bioinformatics Biological Assay Biological Testing Caring Clinical Clinical Chemistry Clinical Trials Collaborations Contraceptive Agents Contraceptive Availability Contraceptive Devices Contract Services Contractor Data Databases Development Devices Discipline Dose Drug Formulations Endocrine Estradiol Estrogen Antagonists Estrogens Estrone Ethinyl Estradiol Evaluation Excretory function Female Female Contraceptive Agents Fertility Fertilization Fetal Growth Follicle Stimulating Hormone Glucocorticoids Government Grant Growth and Development function Guidelines Hematology Hormones Housing Human Hydrocortisone In Vitro Internet Investigational Drugs Investigational New Drug Application Knowledge Laboratory Animals Levonorgestrel Literature Male Contraceptive Agents Mining Monkeys National Institute of Child Health and Human Development Norethindrone Oryctolagus cuniculus Pathology Pharmaceutical Preparations Pharmacology Phase Policies Pregnancy Maintenance Preparation Process Progesterone Progestins Protocols documentation Regulation Research Personnel Rodent Safety Services Site Specific qualifier value Sperm Maturation Sperm Motility Sperm Transport Spermatogenesis Stanolone System Testing Testosterone Thyrotropin Toxic effect Toxicology Tracer United States Public Health Service Urinalysis Vagina Work animal care base contraceptive target design drug discovery drug testing efficacy evaluation implantation in vivo inhibin irritation leydig interstitial cell male next generation nonhuman primate novel novel strategies pre-clinical preclinical evaluation preclinical safety programs receptor binding reproductive sertoli cell sperm morphology stability testing therapeutic candidate user-friendly web app web page web site zygote

项目摘要

One major obstacle in early phase non-steroidal contraceptive discovery and development is limited by known targets and readily accessibility of this information. It is important to facilitate the discovery, curation and availability of contraceptive targets with the aim of developing new approaches to advance next generation of safe contraceptive drug/device. To alleviate this obstacle, bioinformatics driven approach to identify and curate those targets from the existing databases as well as from literature was established. To further allow easy accessibility and friendly user interface for this database, a web application is needed. The Biological Testing Facility has bioinformatics and web design and application capability to achieve this task, in addition to permit rapid evaluation (in vitro and in vivo) of new compositions of matter to the target, efficacy evaluation, safety/ toxicology assessment, drug formulations, delivery systems, and devices for contraceptives followed by clinical batch preparation/ release and continued stability testing of drugs to be evaluated in clinical trials. The BTF provides overall project management and the capabilities to support all phases of novel target product identification, drug discovery/ optimization, preclinical activities and development of contraceptives and associated tasks leading to the filing of investigational new drug (IND) applications

早期阶段非甾体避孕药发现和开发的一个主要障碍是受已知靶点和容易获得这些信息的限制。重要的是要促进避孕目标的发现、管理和提供，目的是开发新的方法来推动下一代安全避孕药物/装置。为了缓解这一障碍，建立了生物信息学驱动的方法来从现有数据库以及文献中识别和管理这些靶标。为了进一步方便访问和友好的用户界面，这个数据库，需要一个网络应用程序。生物试验设施具有完成这项任务的生物信息学和网页设计及应用能力，此外还可进行快速评价（体外和体内）的新组合物的物质的目标，疗效评价，安全性/毒理学评估，药物制剂，输送系统，以及避孕药的装置，然后进行临床批次制备/放行，并对临床试验中要评估的药物进行持续稳定性测试。BTF提供全面的项目管理和能力，以支持新目标产品鉴定、药物发现/优化、临床前活动和避孕药开发的所有阶段，以及导致提交研究性新药（IND）申请的相关任务